• Applied Use-Cases for the One-step TUNEL FITC Apoptosis Dete

  2026-04-24

  Unlock robust, reproducible apoptosis detection in tissue sections and cultured cells with the One-step TUNEL FITC Apoptosis Detection Kit. This guide delivers practical workflow enhancements, troubleshooting strategies, and insights from recent neurotoxicity research, making it indispensable for translational and preclinical labs.

• Bile Acid Metabolism Subtypes Reveal Immune Markers in CRC

  2026-04-23

  Feng et al. (2026) identified molecular subtypes of colorectal cancer (CRC) based on bile acid metabolism, revealing CLCA1, UGT2A3, and ZG16 as key markers linked to immune dysfunction and prognosis. This integrative approach offers new insight into tumor immune microenvironment (TIME) stratification and potential biomarker-driven research.

• RNA Pol II Inhibition Triggers Apoptosis via PDAR, Not mRNA

  2026-04-23

  Harper et al. (2025) demonstrate that inhibition of RNA polymerase II (Pol II) activates cell death through an active signaling pathway termed the Pol II degradation-dependent apoptotic response (PDAR), independent of global transcription loss. This mechanistic insight shifts the paradigm for understanding apoptosis in response to transcriptional inhibition, with implications for cancer therapy research.

• Antimycin A4: An ATP-Citrate Lyase Inhibitor for Energy Rese

  2026-04-22

  Antimycin A4’s dual inhibition of ATP-citrate lyase and the mitochondrial respiratory chain delivers unrivaled precision for dissecting cellular energy metabolism and lipid biosynthesis. Explore how evidence-backed protocols and troubleshooting strategies make this APExBIO compound a gold standard for metabolic, antimicrobial, and disease modeling studies.

• Amikacin (BAY416651): Molecular Insights and Resistance Dyna

  2026-04-22

  Explore how Amikacin (BAY416651), a robust aminoglycoside antibiotic, enables advanced research on bacterial protein synthesis inhibition and resistance gene dynamics. This article uniquely connects molecular mechanisms with practical assay choices, referencing the latest findings on carbapenem-resistant Enterobacter cloacae.

• Mechanisms of Diuron-Induced Acute Kidney Injury: JAK2/STAT1

  2026-04-21

  This study integrates network toxicology and experimental validation to elucidate how Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) induces acute kidney injury (AKI) via JAK2/STAT1 pathway activation. The findings provide a mechanistic foundation for risk assessment and future research on environmental nephrotoxicity.

• Distinct Roles of PSS2 in SREBP Pathway Regulation Revealed

  2026-04-21

  This study delineates the unique regulatory function of human phosphatidylserine synthase 2 (PSS2) in SREBP pathway modulation, contrasting it with its homolog PSS1. High-resolution cryo-EM and lipidomic analyses uncover the substrate specificity and physiological consequences of PSS2 deficiency, advancing our understanding of phospholipid metabolism and its impact on cellular lipid regulation.

• Bortezomib (PS-341): Reliable Proteasome Inhibition in Cell

  2026-04-20

  This article addresses real-world lab challenges in apoptosis and cell viability assays, demonstrating how Bortezomib (PS-341), SKU A2614, provides reproducible, data-driven solutions for proteasome-regulated cellular process research. Scenario-based Q&As guide bench scientists in optimizing protocols, interpreting data, and selecting trustworthy reagents, with evidence-backed insights for advanced oncology and cytotoxicity models.

• Platanoside Attenuates Ferroptosis in Acute Lung Injury via

  2026-04-20

  This study demonstrates that platanoside, a flavonoid glycoside, counteracts ferroptosis in acute lung injury (ALI) by promoting Keap1 degradation and activating the Nrf2/GPX4 axis. The findings reveal a novel autophagy-dependent mechanism for mitigating oxidative damage and preserving tissue integrity in ALI, with implications for future therapeutic strategies.

• Tofacitinib Citrate (CP-690550): Precision in JAK3-Targeted

  2026-04-19

  Explore how Tofacitinib citrate (CP-690550 citrate) enables advanced, highly selective JAK3 inhibition for immune regulation research. This in-depth article reveals novel assay strategies, scientific insights, and protocol optimizations not found in standard guides.

• Pepstatin A: Applied Aspartic Protease Inhibitor Workflows

  2026-04-18

  Pepstatin A enables precise, reproducible inhibition of aspartic proteases across virology, bone metabolism, and cardiovascular research. This article translates the latest workflow-validated insights and comparative data into actionable protocols for advanced experimental models.

• Dextrose (D-glucose): Redefining Immunometabolic Research To

  2026-04-17

  This article examines the pivotal role of Dextrose (D-glucose) in dissecting hypoxia-driven immunometabolism within the tumor microenvironment. By integrating mechanistic insights, evidence-based protocol guidance, and competitive benchmarking, we provide translational researchers with strategic recommendations for leveraging APExBIO's Dextrose to advance metabolic pathway studies, optimize cellular assays, and inform future immunometabolic therapy development.

• Phosbind Acrylamide: Elevating Protein Phosphorylation Analy

  2026-04-16

  Phosbind Acrylamide redefines protein phosphorylation analysis by enabling precise, antibody-free detection of phosphorylation shifts in SDS-PAGE. This workflow-centric guide highlights real-world protocol optimizations, advanced applications, and troubleshooting tips for maximizing research reproducibility using APExBIO's phosphate-binding reagent.

• Disulfiram as a Dopamine β-Hydroxylase Inhibitor in Cancer R

  2026-04-15

  Disulfiram, classically an anti-alcoholism drug, is redefining its role as a dopamine β-hydroxylase inhibitor and proteasome modulator in cancer and inflammasome research. This guide delivers evidence-based protocols, troubleshooting tips, and workflow strategies for leveraging Disulfiram, especially in breast cancer MDA-MB-231 cell line research and pyroptosis modulation.

• Advanced In Vitro Approaches for Evaluating Anticancer Drug

  2026-04-14

  Schwartz's dissertation introduces a nuanced framework for distinguishing between proliferative arrest and cell death in in vitro drug response assays. This refinement enhances mechanistic interpretation and benchmarking of anticancer compounds, offering practical value for translational cancer research.

443 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page